GLPG
DEAD

Serial Number

98094108

Owner

Galapagos NV

Attorney

Alexandra MacKay

Filing Date

Jul 20, 2023

Add to watchlist:

No watchlists yet
View on USPTO

GLPG Trademark

Serial Number: 98094108

GLPG is a trademark filed by Galapagos NV on July 20, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Galapagos NV (19 trademarks)

Mechelen B-2800 , BE

Entity Type: 03

Trademark Details

Filing Date

July 20, 2023

Registration Date

Not Registered

Published for Opposition

October 3, 2023

Goods & Services

pharmaceutical substances and preparations for human use, namely, for the treatment of inflammatory diseases, autoinflammation diseases, autoimmune diseases, proliferative diseases, cancer, skin diseases, cardiovascular diseases, anti-infectives, hepatitis B virus, osteoarthritis, rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma; biopharmaceutical substances and preparations for human use, namely, for the treatment of inflammatory diseases, autoinflammation diseases, autoimmune diseases, proliferative diseases, cancer, skin diseases, cardiovascular diseases, anti-infectives, hepatitis B virus, osteoarthritis, rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma

medical services; medical and pharmaceutical advisory and consultancy services; gene bank services

medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, chimeric antigen receptor T-cell therapy, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields and gathering of data to populate those databases via collection of medical, pharmaceutical, biopharmaceutical research and clinical trial data; gene bank services for research purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 12, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 1, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 28, 2023 NOAM
ASSIGNED TO EXAMINER
Nov 6, 2023 DOCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 3, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 3, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 26, 2023 CNSA
ASSIGNED TO EXAMINER
Aug 21, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2023 NWOS
NEW APPLICATION ENTERED
Jul 24, 2023 NWAP